TPS in Alzheimer’s disease – The 2025 survey highlights clinical experience from institutes worldwide

TPS in Alzheimer's Disease: The 2025 Survey Highlights Clinical Experience from Institutes Worldwide. Transcranial Pulse Stimulation (TPS) continues to advance as an innovative, non-invasive neuromodulation method for patients with Alzheimer's disease. As clinical adoption grows globally, understanding its real-world application is critical for ongoing research and treatment optimization. To gain a comprehensive overview of patient numbers, treatment outcomes, and general clinical experiences, annual surveys are conducted across clinics actively utilizing the therapy. Key Insights from the 2025 Survey:. Global Participation: This year's survey included detailed participation from 33 different institutes and clinics worldwide, reflecting the expanding international footprint of TPS therapy as an add-on treatment option., Clinical Efficacy & Patient Outcomes: The survey aggregates real-world data confirming the therapeutic benefits often seen in clinical trials. Institutions report observable improvements in memory, mood, and overall cognition among treated patients., Unprecedented Precision: A recurring theme among participating clinics is the advantage of the system's highly focal shock wave delivery. TPS enables practitioners to stimulate deep brain areas with unprecedented precision, safely targeting regions critical to Alzheimer's pathology while reducing cortical atrophy. By documenting treatment progress in real-time and sharing clinical experiences across borders, the 2025 survey provides invaluable data that reinforces the potential of TPS as a revolutionary therapeutic concept for managing progressive cognitive decline.